Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01003054 · ClinicalTrials.gov registry record · Phase 2
Autologous Transplantation for Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT01003054: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01003054 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01003054, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The goal of this clinical research is to learn if treatment with high-dose busulfan and cyclophosphamide plus autologous bone marrow transplantation followed by treatment with Gleevec (imatinib mesylate) is effective in treating chronic myelogenous leukemia (CML). Objectives: 1. To assess the efficacy of high dose busulfan-cyclophosphamide and autologous hematopoietic transplantation with post transplant Imatinib mesylate for the treatment of CML. The primary endpoint of the study is to determine the proportion of patients with CML alive in cytogenetic remission at one year following this treatment. 2. Secondary endpoints are time to progression and survival.
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- DRUG Imatinib Mesylate
- PROCEDURE Autologous Stem Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-03 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01003054
The ClinicalTrials.gov registry entry for NCT01003054 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT01003054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01003054 about?
NCT01003054 is a clinical study titled "Autologous Transplantation for Chronic Myelogenous Leukemia". The goal of this clinical research is to learn if treatment with high-dose busulfan and cyclophosphamide plus autologous bone marrow transplantation followed by treatment with Gleevec (imatinib mesylate) is effective in treating chronic myelogenous leukemia (CML). Objectives: 1. To assess the effi...
What is the current status of trial NCT01003054?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2005-03. Estimated completion is 2009-10.
What interventions are being tested in trial NCT01003054?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Imatinib Mesylate (DRUG), Autologous Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT01003054?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.